8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases

被引:218
作者
Montuschi, P
Ciabattoni, G
Paredi, P
Pantelidis, P
du Bois, RM
Kharitonov, SA
Barnes, PJ
机构
[1] Royal Brompton Hosp, Imperial Coll, Sch Med,Interstitial Lung Dis Unit, Natl Heart & Lung Inst,Dept Thorac Med, London SW3 6LY, England
[2] Univ Cattolica Sacro Cuore, Sch Med, Inst Pharmacol, I-00168 Rome, Italy
关键词
D O I
10.1164/ajrccm.158.5.9803102
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Oxidative stress contributes to the pathophysiology of interstitial lung diseases, such as cryptogenic fibrosing alveolitis (CFA), fibrosing alveolitis associated with systemic sclerosis (FASSc) and sarcoidosis. F2-isoprostanes are a series of prostaglandin (PG) F-2-like compounds produced in vivo independent of cyclooxygenase, as products of the radical-catalyzed lipid peroxidation. Measurement of the concentrations of F2-isoprostanes has proved to be valuable in assessing oxidative stress in vivo. The aim of this study was to measure 8-lepi-PGF(2 alpha) concentrations, one of the most abundant F2-isoprostane in humans, in bronchoalveolar lavage (BAL) in normal subjects and to compare them to those observed in patients with CFA (n = 9), FASSc (n = 8) and sarcoidosis (n = 10). 8-epi-PGF(2 alpha) was detectable in PAL fluid in normal subjects (9.6 +/- 0.8 pg/ml) and its concentrations were increased approximately 5-fold in patients with CFA (47.4 +/- 7.0, p < 0.001) and FASSc (43.2 +/- 3.3, p < 0.001). 8-epi-PGF(2 alpha) was also increased in patients with sarcoidosis, although to a lesser extent (12.0 +/- 0.70 pg/ml, p < 0.01). No correlation between 8-epi-PGF(2 alpha) and either lung function tests or BAL cell types was observed in any group of patients. Our study shows that the level of oxidative stress is enhanced in patients with interstitial lung diseases as reflected by increased concentrations of 8-epi-PGF(2 alpha) in BAL fluid.
引用
收藏
页码:1524 / 1527
页数:4
相关论文
共 35 条
[11]   Serum indicators of free radical activity in idiopathic pulmonary fibrosis [J].
Jack, CIA ;
Jackson, MJ ;
Johnston, IDA ;
Hind, CRK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (06) :1918-1923
[12]  
KAYGANICHHARRISON KA, 1993, J LIPID RES, V34, P1229
[13]   Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract [J].
Kharitonov, SA ;
Chung, KF ;
Evans, D ;
OConnor, BJ ;
Barnes, PJ .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (06) :1773-1780
[14]  
KIEMLEKALLEE J, 1991, EUR RESPIR J, V4, P400
[15]  
Klein T, 1997, J PHARMACOL EXP THER, V282, P1658
[16]   Oxidized BAL fluid proteins in patients with interstitial lung diseases [J].
Lenz, AG ;
Costabel, U ;
Maier, KL .
EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (02) :307-312
[17]   OXIDANTS ANTIOXIDANTS IN IDIOPATHIC PULMONARY FIBROSIS [J].
MACNEE, W ;
RAHMAN, I .
THORAX, 1995, 50 :S53-S58
[18]   CHRONIC DIFFUSE INFILTRATIVE LUNG-DISEASE - COMPARISON OF DIAGNOSTIC-ACCURACY OF CT AND CHEST RADIOGRAPHY [J].
MATHIESON, JR ;
MAYO, JR ;
STAPLES, CA ;
MULLER, NL .
RADIOLOGY, 1989, 171 (01) :111-116
[19]   LOGICAL CREATIVITY [J].
MORRIS, HC .
THEORY & PSYCHOLOGY, 1992, 2 (01) :89-107
[20]   INCREASE IN CIRCULATING PRODUCTS OF LIPID-PEROXIDATION (F-2-ISOPROSTANES) IN SMOKERS - SMOKING AS A CAUSE OF OXIDATIVE DAMAGE [J].
MORROW, JD ;
FREI, B ;
LONGMIRE, AW ;
GAZIANO, JM ;
LYNCH, SM ;
SHYR, Y ;
STRAUSS, WE ;
OATES, JA ;
ROBERTS, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (18) :1198-1203